Navigation Links
Telik Announces Initiation of a Phase 2b Clinical Trial of Telintra® (Ezatiostat HCL) in Patients With Low to Intermediate-1 Risk Non-Deletion (5q) Myelodysplastic Syndrome
Date:10/13/2011

PALO ALTO, Calif., Oct. 13, 2011 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) today announced the initiation of a Phase 2b clinical trial to evaluate Telintra treatment of patients with Low to Intermediate-1 IPSS Risk, transfusion dependent, non-deletion (5q) myelodysplastic syndrome (MDS), who have not been treated with hypomethylating agents (HMA) such as Vidaza® or Dacogen®.  This patient population represents the majority of MDS patients and a significant unmet medical need.  

This multicenter trial is intended to enroll up to 145 evaluable patients with 2 planned interim analyses, the first of which will be performed when data from 49 evaluable patients are available; and the second at 97 evaluable patients. The primary objective of the trial is to determine the hematologic improvement-erythroid response rate as determined by clinically significant transfusion reduction or independence, in accordance with International Working Group MDS criteria (2006). Secondary objectives include determination of response rates of increasing neutrophil and platelet levels, and safety.  Pretreatment bone marrow samples from selected patients may be obtained to confirm genomic results obtained in previous studies.      

In a similar, HMA-naive, transfusion-dependent population of 19 patients, 12 patients (63%) treated with Telintra achieved either clinically significant, according to International Working Group 2006 criteria, transfusion reductions (9 patients), or complete transfusion independence (3 patients), as previously reported in the journal Cancer (Raza, A., et al., doi: 10.1002/cncr.26469, September 1, 2011).  Telintra was also shown to have multilineage responses resulting in improvement in MDS patients who additionally had low levels of neutrophils and/or platelets and, therefore, may offer an advantage in the treatment
'/>"/>

SOURCE Telik, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Telik Announces Publication in the Journal Cancer of a Phase 2 Randomized Multicenter Study of Two Extended Dosing Schedules of Oral Ezatiostat in Low to Intermediate-1 Risk Myelodysplastic Syndrome
2. Telik Announces First Quarter 2011 Financial Results
3. Telik Announces Presentation of New Data on the Characterization of Novel Ezatiostat (TELINTRA®, TLK199) Analogs at American Association for Cancer Research Annual Meeting
4. Telik Announces Presentation and Webcast at 10th Annual Needham Healthcare Conference
5. Telik Announces Fourth Quarter and 2010 Year End Financial Results and 2011 Financial Guidance
6. Telik Announces Presentation and Webcast at 13th Annual BIO CEO & Investor Conference
7. Telik Announces Presentation at American Society of Hematology Annual Meeting
8. Telik Announces Third Quarter 2010 Financial Results
9. Telik Awarded $1.2 Million in Grants for Qualifying Therapeutic Development Projects
10. Telik Announces Publication of Review Focused on the Inhibition of the Enzyme GSTP1-1 as a Target for New Cancer Treatments
11. Telik Announces Publication of a Case Report of a Sustained Hematologic Response in Myelodysplastic Syndrome Following an Abbreviated Exposure to Oral Telintra(R) (Ezatiostat HCl)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... , Oct. 31, 2014  Zacks.com announces the list of stocks ... analysts discuss the latest news and events impacting stocks and the ... AMGN - Free Report ), Celgene (Nasdaq: ... BIIB - Free Report ), Market Vectors Biotech ETF ... S&P Biotech ETF (AMEX: XBI - Free Report ...
(Date:10/31/2014)... , Oct. 31, 2014 /CNW Telbec/ - ... with its strategic plan, for accelerated growth in terms ... 32.6% and revenues reached $17,862,341. Net income amounted to ... threshold for the first time in the Company,s history. ... the Company joined the forces of its subsidiaries, merging ...
(Date:10/31/2014)... 2014 Though therapies are in their nascent ... show an annual increase of 16.2% over the 2010-2020 ... billion, according to Kalorama Information,s report, Stem Cell ... therapeutics that have gained or are expected to gain ... developers tackle ever more complicated conditions, stem cell therapies ...
Breaking Medicine Technology:The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 2The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 3The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 4The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 5The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 6The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 7Results for the fourth quarter and the fiscal year ended June 30, 2014 - Ergoresearch reports solid 2014 annual results 2Results for the fourth quarter and the fiscal year ended June 30, 2014 - Ergoresearch reports solid 2014 annual results 3Results for the fourth quarter and the fiscal year ended June 30, 2014 - Ergoresearch reports solid 2014 annual results 4Results for the fourth quarter and the fiscal year ended June 30, 2014 - Ergoresearch reports solid 2014 annual results 5Report: Stem Cell Technologies Market Growing 2
(Date:10/31/2014)... 31, 2014 Fundraising support for fighting cancer ... than losses. At noon on Monday, November 10 in the ... (SSMH), greater than 20 Susquehanna Health (SH) employees and community ... awareness and funds for the new Cancer Center at SSMH. ... for this act of love and support to which many ...
(Date:10/31/2014)... first study of its kind, Rice University researchers have ... cause cancer cells to become metastatic. The research reveals ... cells to both migrate and form new tumors. Researchers ... drugs that interfere with the genetic switches that cancer ... circulating tumor cells -- two of the main players ...
(Date:10/31/2014)... October 31, 2014 The Memory Healer review ... by Alexander Lynch, whose father suffered from Alzheimer's disease. ... moment, caused by his father's disease. His father pointed a ... the crucial moment when the author of this method understood ... , The Memory Healer program is based on years ...
(Date:10/31/2014)... CA (PRWEB) October 31, 2014 ... also has amazing health effects for practitioners. ... by a Doctor of Science and Movement specializing ... his dedication to pelvic floor reeducation that traditional ... urinary incontinence, Diastasis Recti, Prolepses, etc. , The ...
(Date:10/31/2014)... Lake City, UT (PRWEB) October 31, 2014 ... announce the new Activz Silver line offering ... and cleansing wipes. For over a century, silver has ... formula found in Activz Silver products is the most ... U.S. patents, has a unique chemical structure that supports ...
Breaking Medicine News(10 mins):Health News:Susquehanna Health Soldiers + Sailors Memorial Hospital Razing Heads to Fight Cancer 2Health News:Decoding the emergence of metastatic cancer stem cells 2Health News:Decoding the emergence of metastatic cancer stem cells 3Health News:"Memory Healer" Review Reveals a New Natural Remedy Guide for Managing Memory Loss 2Health News:Super Models and European Celebrities’ Secret Flat Tummy System Comes to America 2Health News:Super Models and European Celebrities’ Secret Flat Tummy System Comes to America 3Health News:New Collection of Nano-particle Natural Silver Products by Activz Whole-Food Nutrition 2Health News:New Collection of Nano-particle Natural Silver Products by Activz Whole-Food Nutrition 3Health News:New Collection of Nano-particle Natural Silver Products by Activz Whole-Food Nutrition 4
... News) -- Heart disease patients with high blood pressure ... drugs (NSAIDs) are at greater risk for heart attack, ... NSAIDS include popular medications such as such as aspirin, ... are published in the July issue of The ...
... Gordon HealthDay Reporter , THURSDAY, July 14 (HealthDay News) ... you probably memorized a lot more information -- such as phone ... a new study has found that the brain just doesn,t remember ... been saved on a computer. What people may remember, however, is ...
... transplant survival more than doubled in recent years for ... Research Hospital, with patients who lacked genetically matched donors ... to be the best ever reported for leukemia patients ... expected to make transplantation a treatment option for more ...
... can be admirable or romantic. In a cancerous tumor, it ... cells that have strayed from their original location to insinuate their ... way of determining whether a newly formed tumor is more likely ... the body. In a study published in the July 12 ...
... percent of patients with primary or metastatic cancer ... seizures, confusion, difficulty swallowing and visual disturbances. These ... brain invasion from cancer called neoplastic meningitis. Santosh ... San Diego School of Medicine and colleagues have ...
... 14 (HealthDay News) -- New research suggests that training ... other people could help them overcome anxiety and prevent ... Oxford University in the United Kingdom found that training ... negative interpretations of unclear social situations could influence how ...
Cached Medicine News:Health News:Certain Painkillers May Raise Odds of Stroke, Heart Attack: Study 2Health News: Can You Google Your Memory? 2Health News: Can You Google Your Memory? 3Health News: Can You Google Your Memory? 4Health News:Bone marrow transplant survival more than doubles for young high-risk leukemia patients 2Health News:Bone marrow transplant survival more than doubles for young high-risk leukemia patients 3Health News:Early-stage melanoma tumors contain clues to metastatic potential 2Health News:Early-stage melanoma tumors contain clues to metastatic potential 3Health News:Novel combined therapy extends life, diminishes pain in brain cancer patients 2Health News:Training in Positive Thinking May Help Anxious Teens 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: